CD38 and Miyoshi myopathy: Particularly, relapsed/refractory MM (RRMM) patients already exposed to PIs, IMiDs, and anti-CD38 mAbs (referred to as triple-class exposed, TCE) have a poor prognosis using standard treatments, with a median progression-free survival (PFS) of approximately 4.5 months and a median OS slightly higher than 1 year [6], supporting a need for treatments with novel mechanisms of action.